Skip to main content
SpringerLink
Log in

FKB238: A Bevacizumab Biosimilar

  • Adis Biosimilar Brief
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

FKB238 is a biosimilar of bevacizumab (a monoclonal antibody against vascular endothelial growth factor) approved for use in the same types of cancer as reference bevacizumab. FKB238 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic similarity was shown in healthy volunteers and in patients with non-small cell lung cancer (NSCLC). FKB238 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with advanced or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. European Medicines Agency. Equidacent: CHMP assessment report. 2020. https://www.ema.europa.eu/en/documents/assessment-report/equidacent-epar-public-assessment-report_en.pdf. Accessed 19 Jul 2021

  2. Kaito H, van den Berg F, Niewiarowski A, et al. A randomized, double-blind, single dose comparison of pharmacokinetics and safety of FKB238 with bevacizumab [abstract no. e14007]. J Clin Oncol. 2017;35(Suppl 15).

  3. Syrigos K, Abert I, Andric Z, et al. Efficacy and safety of bevacizumab biosimilar FKB238 versus originator bevacizumab: results from AVANA, a phase III trial in patients with non-squamous non-small-cell lung cancer (non-sq-NSCLC). BioDrugs. 2021. https://doi.org/10.1007/s40259-021-00489-4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. European Medicines Agency. Equidacent (bevacizumab): summary of product characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/equidacent-epar-product-information_en.pdf. Accessed 19 Jul 2021

Download references

Acknowledgements

During the peer review process the manufacturer of FKB238 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Yahiya Y. Syed

Authors
  1. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yahiya Y. Syed.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

The manuscript was reviewed by: K. Araki, Department of Medical Oncology, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan; P. Gascon, Laboratory of Molecular and Translational Oncology, CELLEX, Barcelona, Spain.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 47 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. FKB238: A Bevacizumab Biosimilar. Clin Drug Investig 41, 825–828 (2021). https://doi.org/10.1007/s40261-021-01065-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-021-01065-y

Search

Navigation